{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T22:44:55Z","timestamp":1777157095404,"version":"3.51.4"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,1,14]],"date-time":"2008-01-14T00:00:00Z","timestamp":1200268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p><jats:bold>Objectives: <\/jats:bold> Pulmonary aspergillosis in immunosuppressed patients is associated with significant mortality and morbidity. We assessed the prophylactic and therapeutic effect of nebulized amphotericin B (AmB) on mortality of immunosuppressed animals with pulmonary aspergillosis in this meta\u2010analysis.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Literature search was based on MEDLINE (1966 to January 15, 2007), EMBASE, and Cochrane\u2010Controlled Trials Register (2006 issue 4) databases. Only randomized\u2010controlled studies comparing nebulized AmB with placebo on immunosuppressed animals were included. Two reviewers reviewed and extracted the data independently.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Eight studies including 839 immunosuppressed animals were considered. The overall mortality of the immunosuppressed animals with pulmonary aspergillosis treated with nebulized AmB was reduced (69.4% versus 87.7%, odds ratio [OR] 0.12, 95% confidence interval [CI]: 0.08\u20130.19; <jats:italic>P<\/jats:italic>&lt;0.0001). The effect of nebulized AmB on mortality was more significant when the drug was administered as prophylaxis before the inoculation of <jats:italic>Aspergillus fumigatus<\/jats:italic> (OR 0.07, 95% CI: 0.03\u20130.12, <jats:italic>P<\/jats:italic>=0.0001; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>=0) than as a therapeutic agent (OR 0.20, 95% CI: 0.11\u20130.36, <jats:italic>P<\/jats:italic>&lt;0.0001; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>=0) (ratio of the 2 ORs=2.86, 95% CI: 1.03\u20136.11; <jats:italic>P<\/jats:italic>=0.04). The effectiveness of AmB desoxycholate (OR 0.16, 0.06\u20130.38, <jats:italic>P<\/jats:italic>&lt;0.0001; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>=0) and lipid\u2010associated (liposomal, or lipid complex or colloidal dispersion) amphotericin (OR 0.11, 95% CI: 0.06\u20130.20, <jats:italic>P<\/jats:italic>&lt;0.0001; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>=0) was not significantly different (ratio of the 2 ORs=1.46, 95% CI: 0.49\u20134.39; <jats:italic>P<\/jats:italic>=0.50). Three studies evaluated the potential side effects of nebulized amphotericin and showed that there was no significant renal toxicity but the amphotericin desoxycholate had some detrimental effects on pulmonary surfactant function.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> The use of nebulized amphotericin, either as a prophylactic or therapeutic agent, is effective in reducing mortality of immunosuppressed animals with pulmonary aspergillosis. A large randomized controlled trial is needed to confirm whether combining nebulized amphotericin with systemic antifungal agents will reduce mortality in immunosuppressed patients with suspected or proven pulmonary aspergillosis.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2007.00290.x","type":"journal-article","created":{"date-parts":[[2008,5,16]],"date-time":"2008-05-16T06:57:58Z","timestamp":1210921078000},"page":"168-176","source":"Crossref","is-referenced-by-count":14,"title":["Meta\u2010analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals"],"prefix":"10.1111","volume":"10","author":[{"given":"K.M.","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Duff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.3.4S.33151"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G477"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2006.00156.x"},{"key":"e_1_2_6_5_2","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies","volume":"91","author":"Pagano L","year":"2006","journal-title":"the SEIFEM-2004 study"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x"},{"key":"e_1_2_6_7_2","first-page":"624","article-title":"Invasive aspergillosi","volume":"136","author":"Garbino J","year":"2006","journal-title":"is treatment with \u201cinexpensive\u201d amphotericin B cost saving if \u201cexpensive\u201d voriconazole is only used on demand?"},{"key":"e_1_2_6_8_2","first-page":"579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours","volume":"322","author":"Eriksson U","year":"2001","journal-title":"randomised controlled trial"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050521"},{"key":"e_1_2_6_10_2","first-page":"619","article-title":"Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome)","volume":"52","author":"Ruijgrok EJ","year":"2000","journal-title":"aerosol characteristics and in-vivo amphotericin B deposition in rats"},{"key":"e_1_2_6_11_2","first-page":"3654","article-title":"Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia","volume":"93","author":"Schwartz S","year":"1999","journal-title":"results of a prospective randomized multicenter trial"},{"key":"e_1_2_6_12_2","unstructured":"RijndersBJ CornelissenJJ SlobbeL et al. Aerosolized liposomal amphotericin\u2010B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia. Randomized placebo\u2010controlled trial. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2006 M1308\u2010c."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780500051919"},{"key":"e_1_2_6_14_2","first-page":"219","article-title":"Interaction revisited","volume":"326","author":"Altman DG","year":"2003","journal-title":"the difference between two estimates"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_6_16_2","first-page":"455","article-title":"Trim and fill","volume":"56","author":"Duval S","year":"2000","journal-title":"a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis"},{"key":"e_1_2_6_17_2","first-page":"1289","article-title":"Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis","volume":"57","author":"Ruijgrok EJ","year":"2005","journal-title":"evidence for long-term biological activity"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.41.2.259","article-title":"Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis","volume":"41","author":"Cicogna CE","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.6.1001"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1128\/jcm.29.7.1317-1322.1991","article-title":"Model of recurrent pulmonary aspergillosis in rats","volume":"29","author":"Niki Y","year":"1991","journal-title":"J Clin Microbiol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.11.1676"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1852-1854.2006"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.1.89"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.3028-3030.2005"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00315-06"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01268-06"},{"key":"e_1_2_6_27_2","first-page":"68","article-title":"Treatment of patients with pulmonary aspergillosis by means of inhalation of amphotericin B aerosols","author":"Minsker OB","year":"1983","journal-title":"Probl Tuberk"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01197.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-0767"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000101516.08327.A9"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2007.00290.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2007.00290.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:20:47Z","timestamp":1697296847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2007.00290.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,14]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1399-3062.2007.00290.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2007.00290.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,14]]}}}